Na An

Title: Na An - Innovator in Cancer Treatment

Introduction

Na An is a notable inventor based in Shijiazhuang, China. He has made significant contributions to the field of oncology, particularly in the treatment of peripheral T-cell lymphoma (PTCL). His innovative approach combines various therapeutic agents to enhance treatment efficacy and patient safety.

Latest Patents

Na An holds a patent for the use of mitoxantrone hydrochloride liposome in combination with cyclophosphamide, vincristine, and prednisone. This patent outlines a method for treating treatment-naïve PTCL patients. The combined administration of these drugs is designed to be safe and tolerable, with minimal toxicity and side effects. The method aims to achieve a higher total objective remission rate (ORR) in patients suffering from this aggressive form of lymphoma.

Career Highlights

Na An is associated with Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. His work focuses on developing innovative therapies that improve patient outcomes in cancer treatment. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Na An collaborates with talented professionals in his field, including Chunlei Li and Xuefang Xia. Their combined expertise contributes to the advancement of cancer treatment methodologies.

Conclusion

Na An's contributions to cancer treatment through his innovative patent demonstrate his commitment to improving patient care. His work continues to influence the field of oncology and offers hope for better treatment options for patients with PTCL.